ClinicalTrials.gg
Active, not recruitingNCT05064878GEMZUpdated Apr 29, 2026

A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.

A Phase 3 interventional study of Fenfluramine and Placebo in CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure and Epileptic Spasm, sponsored by Zogenix, Inc.. Active, not recruiting at 46 sites in 14 countries. Open to participants aged 1 Year to 35 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Zogenix, Inc. (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
1 Year to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Epilepsy, Tonic-Clonic with a site in United States — 1 open to participants now, 2 under way, 2 of them phase 3. Epilepsy, Tonic-Clonic · United States.

Enrollment
8th of 10
87 · median 134
Started
2022
with 1 other
Phase 3
3 of 11
1 open now
Registered
9th of 11
by date
Lead sponsor
1 of 11
Zogenix, Inc.

Among the 11 studies in Epilepsy, Tonic-Clonic with a site in United States, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2022, is one of 3 in phase 3, and was the 9th registered.

Epilepsy, Tonic-Clonic

23 studies on the registry are indexed under Epilepsy, Tonic-Clonic; 3 are open to participants now.

Browse Epilepsy, Tonic-Clonic studies →

Open to participants now

1 of the 11 studies in Epilepsy, Tonic-Clonic with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 2 Epilepsy, Tonic-Clonic studies recruiting now, 1 sets no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 1 Year to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Epilepsy, Tonic-Clonic with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3 Study to examine the efficacy and safety of ZX008 in children and adults with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder (CDD).

Read the detailed description

This is an up to 3-part multicenter study: a double-blind, placebo-controlled part (Part 1) which includes Baseline Period (4 weeks), Titration Period (2 weeks), Maintenance Period (12 weeks) and Transition Period (2 weeks), followed by up to 2 open-label extension (OLE) parts: Part 2 of 54 weeks [Treatment Period (52 weeks), Taper Period (2 weeks)] and Part 3, i.e., OLE1 and OLE2, respectively, with the addition of the second OLE part (Part 3/OLE2) only for participants who will continue on fenfluramine and have no alternative treatment access from another source (e.g., a managed access program [MAP]). Participants can remain in Part 3 until MAP access or approval of fenfluramine (ZX008) has been obtained from regulatory authorities for CDD in the participant's country of residence, or until the investigational product development for CDD is stopped by the Sponsor, whichever comes first. Participants who discontinue early from Part 1, Part 2, or Part 3 will attend a Cardiac Follow-Up Visit 6 months after their last dose of study drug.

03

Conditions studied

  • CDKL5 Deficiency Disorder
  • Generalized Tonic Clonic Seizure
  • Epileptic Spasm
  • Refractory Seizures

Keywords

  • CDD
  • CDKL5
  • fenfluramine
04

Who can participate

Ages eligible
1 Year to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has a confirmed pathogenic or likely pathogenic mutation in the CDKL5 gene and a clinical diagnosis of CDKL5 deficiency disorder (CDD) with epilepsy onset in the first year of life, plus motor and developmental delays.
  • Subject is male or female, aged 1 to 35 years, inclusive, as of the day of the Screening Visit.
  • Subject must have failed to achieve seizure control despite previous or current use of 2 or more antiepileptic treatments (AETs).
  • Subject is currently receiving at least 1 concomitant antiseizure treatment: antiseizure medication (ASM), vagus nerve stimulation (VNS), responsive neurostimulation (RNS), or ketogenic diet (KD).
  • All medications or interventions for epilepsy (including VNS, RNS, and KD) must be stable prior to screening and are expected to remain stable throughout the study.
  • At the Screening Visit, parent/caregiver reports that subject has ≥ 4 countable motor seizures (CMS) per week.

Exclusion criteria

Exclusion Criteria:

  • Subject has a known to fenfluramine or any of the in the study drug.
  • Subject has a diagnosis of pulmonary arterial hypertension.
  • Subject has a medical condition, including , interstitial lung disease, or portal hypertension, or has had clinically relevant symptoms or a clinically significant illness currently or in the 4 weeks prior to the Screening Visit, other than epilepsy, that would negatively impact study participation, collection of study data, or pose a risk to the subject.
  • Subject has current or past history of cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, myocardial infarction or stroke, severe ventricular arrhythmias, or clinically significant structural cardiac abnormality, including but not limited to mitral valve prolapse, atrial or ventricular septal defects, patent ductus arteriosus, and patent foramen ovale with reversal of shunt. (Note: Patent foramen ovale or a bicuspid aortic valve are not considered exclusionary).
  • Subject has current eating disorder that suggests anorexia nervosa or bulimia.
  • Subject has a current or past history of glaucoma.
  • Subject is taking > 4 concomitant antiseizure medications (ASMs). Rescue medications are not included in the count.
  • Subject is receiving concomitant treatment with cannabidiol (CBD) other than Epidiolex/Epidyolex or is being actively treated with tetrahydrocannabinol (THC) or any marijuana product for any condition.
  • Subject has moderate to severe hepatic impairment.
  • Subject is currently receiving another product(s) or has received another investigational product within 30 days or within \< 5 times the half-lives of the investigational product, whichever is longer, prior to the Screening Visit.
  • Subject has previously been treated with Fintepla® (fenfluramine) prior to the Screening Visit.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Fenfluramine (hydrochloride) 0.8 mg/kg/day

    Part 1: Fenfluramine (hydrochloride) 0.8 mg/kg/day will be administered twice a day (BID) in equally divided doses; maximum of 30 mg/day, (subjects taking concomitant stiripentol will receive 0.5 mg/kg/day, \[maximum of 20 mg/day\]) with or without food.

    Drug: Fenfluramine

  • Placebo comparator
    Placebo

    Part 1: Matching fenfluramine (hydrochloride) placebo will be administered twice a day (BID) in equally divided doses with or without food.

    Drug: Placebo

  • Experimental
    Fenfluramine (hydrochloride) Open-label

    Part 2 and Part 3: Open-label fenfluramine (hydrochloride) will be administered using a flexible dosing regimen, up to fenfluramine 0.8 mg/kg/day; maximum dose: 30 mg/day (subjects taking concomitant stiripentol will receive 0.5 mg/kg/day, \[maximum of 20 mg/day\]). Fenfluramine (hydrochloride) will be administered twice a day (BID) in equally divided doses with or without food.

    Drug: Fenfluramine

Interventions

  • Fenfluramine is supplied as an oral aqueous solution of fenfluramine hydrochloride.

    Also known as: FINTEPLA, ZX008, fenfluramine HCl, fenfluramine hydrochloride

  • DrugPlacebo

    Matching fenfluramine (hydrochloride) placebo is supplied as an oral solution.

06

What researchers measure

Primary outcomes

  1. Percentage Change from Baseline in Countable Motor Seizure Frequency (CMSF) (Part 1)

    The median percentage change from the Baseline in monthly (per 28 days) CMSF during the combined Titration and Maintenance Periods with the fenfluramine (ZX008) 0.8 mg/kg/day group compared with the placebo group will be reported.

    Time frame: Baseline (28 days), Combined Titration and Maintenance (T+M) Periods (14 weeks)

  2. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) (Part 2)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Treatment Emergent Adverse Events (TEAEs) are defined as any AEs reported on or after the first dose of study medication.

    Time frame: Up to OLE1 Treatment Period Post-Dose Safety Follow-up Visit 17 (up to 70 weeks)

  3. Percentage of Participants With Abnormal Physical Examination Findings (Part 2)

    Abnormal findings of physical exam that is considered clinically significant by Principal Investigator (PI).

    Time frame: Up to End of Treatment (EoT)/Early Termination (ET) Visit 16 of OLE1 Treatment Period (up to 68 weeks)

  4. Percentage of Participants With Abnormal Neurological Examination Findings (Part 2)

    Abnormal findings of neurological exam that is considered clinically significant by PI.

    Time frame: Up to EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)

  5. Percentage of Participants with Positive Response to Self-harm Question (Part 2)

    Time frame: OLE1 Treatment Period Day 1 to OLE1 Treatment Period Post-Dose Safety Follow-up Visit 17 (up to 70 weeks)

  6. Percentage of Participants with Increase in Valvular Regurgitation from Baseline (except absent to trace) (Part 2)

    Valvular regurgitation will be assessed using a 2-dimensional (2-D) Color Doppler Echocardiography (ECHO).

    Time frame: Baseline (28 days), Cardiac Follow-up Visit 18 (up to 96 weeks)

  7. Percentage of Participants with Pulmonary Arterial Hypertension (PASP > 35 mmHg) at any Time During Treatment on Repeat Testing (Part 2)

    Time frame: OLE1 Treatment Period Day 1 to EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)

  8. Change from Baseline in Laboratory Parameters (Hematology) (Part 2)

    Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)

  9. Change from Baseline in Laboratory Parameters (Hormones) (Part 2)

    Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)

  10. Change from Baseline in Laboratory parameters (Chemistry) (Part 2)

    Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)

  11. Change from Baseline in Laboratory Parameters (Urinalysis) (Part 2)

    Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)

  12. Change from Baseline in Vital Signs (Blood pressure) (Part 2)

    Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)

  13. Change from Baseline in Vital Signs (Heart rate) (Part 2)

    Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)

  14. Change from Baseline in Vital Signs (Temperature) (Part 2)

    Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)

  15. Change from Baseline in Vital Signs (Respiratory rate) (Part 2)

    Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)

  16. Change from Baseline in Body Weight (Part 2)

    Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)

  17. Change from Baseline in Tanner Staging (Part 2)

    Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)

  18. Percentage of Participants with TEAEs (Part 3)

    An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Treatment Emergent Adverse Events are defined as any AEs reported on or after the first dose of study medication.

    Time frame: Up to OLE2 Period Post-Dose Safety Follow-up (up to 200 weeks)

  19. Change from Baseline in Height (Part 3)

    Time frame: Baseline (28 days), OLE2 Period EoT/ET Visit 23 (up to 198 weeks)

  20. Change from Baseline in Body Weight (Part 3)

    Time frame: Baseline (28 days), OLE2 Period EoT/ET Visit 23 (up to 198 weeks)

  21. Percentage of Participants with Increase in Valvular Regurgitation from Baseline (except absent to trace) (Part 3)

    Valvular regurgitation will be assessed using a 2 D Color Doppler ECHO.

    Time frame: Baseline (28 days), Cardiac Follow-up Visit (up to 295 weeks)

  22. Percentage of Participants with Pulmonary Arterial Hypertension (PASP > 35 mmHg) at any Time During Treatment on Repeat Testing (Part 3)

    Time frame: OLE2 Period Day 1 to EoT/ET Visit 23 of OLE2 Period (up to 198 weeks)

Secondary outcomes

  1. Percentage of Participants Who Achieve a ≥ 50% Reduction from Baseline in CMSF (Part 1)

    The percentage of participants who achieve a ≥ 50% reduction from Baseline in CMSF during T+M periods, in the fenfluramine 0.8 mg/kg/day group compared with the placebo group.

    Time frame: Baseline (28 days), Combined T+M Periods (14 weeks)

  2. Percentage of Participants with a Clinical Global Impression-Improvement (CGI-I) Rating of 'Much Improved' or 'Very Much Improved' as Assessed by Investigator (Part 1)

    The percentage of participants who achieve a CGI-I rating of much or very much improved as assessed by the Investigator at the end of T+M periods, in the fenfluramine 0.8 mg/kg group compared with the placebo group. The CGI-I rating scale permits a global evaluation of the participant's improvement over time. The severity of a participant's condition is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.

    Time frame: At the end of the combined T+M Periods (14 weeks)

  3. Percentage Change From Baseline in Monthly Generalized Tonic-Clonic (GTC) Seizure Frequency (Part 1)

    The median percentage change from Baseline in monthly GTC seizure frequency during T+M periods, in the fenfluramine 0.8 mg/kg/day group compared with the placebo group.

    Time frame: Baseline (28 days), Combined Titration and Maintenance (T+M) Periods (14 weeks)

  4. Categorized Percentage Change in Seizures from Baseline in CMSF (Part 1)

    The categorized median percentage change in seizures from the Baseline in monthly (per 28 days) CMSF during the combined T+ M periods will be presented in the following categories: no reduction or worsening, ≥25%, ≥75%, or 100% reduction.

    Time frame: Baseline (28 days), Combined Titration and Maintenance (T+M) Periods (14 weeks)

  5. Percentage of Participants who Achieve "Near Seizure Freedom" (Part 1)

    The percentage of participants who achieve near seizure freedom, defined as 0 or 1 seizures, during T+M, in the fenfluramine 0.8 mg/kg/day group compared with the placebo group.

    Time frame: Combined T+M Periods (14 weeks)

  6. Percentage of Participants with a CGI-I Rating of 'Much Improved' or 'Very Much Improved' as Assessed by the Parent/Caregiver (Part 1)

    The percentage of participants who achieve a CGI-I rating of much or very much improved as assessed by the by the parent/caregiver at the end of T+M periods, in the fenfluramine 0.8 mg/kg group compared with the placebo group.

    Time frame: At the end of the combined T+M Periods (14 weeks)

  7. Percentage of Participants with Improvement (Minimal, Much or Very Much Improved) on the CGI-I Rating as Assessed, Independently, by the Investigator (Part 1)

    The percentage of participants who achieve a CGI-I rating of minimal, much or very much improved as assessed, independently, by the Investigator at the end of T+M periods, in the fenfluramine 0.8 mg/kg group compared with the placebo group.

    Time frame: At the end of the combined T+M Periods (14 weeks)

  8. Percentage of Participants with Improvement (Minimal, Much or Very Much Improved) on the CGI-I Rating as Assessed, Independently, by the Parent/Caregiver (Part 1)

    The percentage of participants who achieve a CGI-I rating of minimal, much or very much improved as assessed, independently, by the parent/caregiver at the end of T+M periods, in the fenfluramine 0.8 mg/kg group compared with the placebo group.

    Time frame: At the end of the combined T+M Periods (14 weeks)

  9. Percentage Change from Baseline in the Monthly Frequency of all Seizures (Part 1)

    The percentage change from the Baseline in the monthly (per 28 days) frequency of all seizures during the combined T+M period.

    Time frame: Baseline (28 days), Combined Titration and Maintenance (T+M) Periods (14 weeks)

  10. Change from Baseline in the Monthly Frequency of Countable Motor Seizure (CMS)-free Days (Part 1)

    The change from the Baseline in the monthly (per 28 days) frequency of CMS-free days during the combined T+M periods.

    Time frame: Baseline (28 days), Combined Titration and Maintenance (T+M) Periods (14 weeks)

  11. Percentage of Participants with TEAEs (Part 1)

    An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. A TEAEs was defined as any adverse events with a start date/time on or after dosing of the study medication and up to end of the maintenance period (14 weeks) inclusive after dosing of the study medication.

    Time frame: From Day of first dose to the End of the Maintenance Periods (up to 14 weeks)

  12. Percentage of Participants With Abnormal Physical Examination Findings (Part 1)

    Time frame: Baseline, Visit 6 (Day 43), Visit 7 (Day 71), Visit 8 (Day 99)

  13. Percentage of Participants With Abnormal Neurological Examination Findings (Part 1)

    Time frame: Baseline, Visit 6 (Day 43), Visit 8 (Day 99)

  14. Percentage of Participants with Positive Response to Self-harm question (Part 1)

    Time frame: Baseline, Visit 5 (Day 15), Visit 6 (Day 43), Visit 7 (Day 71), Visit 8 (Day 99)

  15. Percentage of Participants with Increase in Valvular Regurgitation from Baseline (except absent to trace) (Part 1)

    Valvular regurgitation will be assessed using a 2-D Color Doppler ECHO.

    Time frame: From Day of first dose to the End of the Maintenance Period (up to 14 weeks)

  16. Percentage of Participants with Pulmonary Arterial Hypertension (PASP > 35 mmHg) at any Time During Treatment on Repeat Testing (Part 1)

    The safety and tolerability of fenfluramine (ZX008) will be assessed in pediatric and adult participants with CDD.

    Time frame: From Day of first dose to the End of the Maintenance Period (up to 14 weeks)

  17. Change from Baseline in Laboratory parameters (Hematology) (Part 1)

    Time frame: Baseline (28 days), end of the combined Titration and Maintenance (T+M) Periods (Day 99)

  18. Change from Baseline in Laboratory parameters (Hormones) (Part 1)

    Time frame: Baseline (28 days), end of the combined Titration and Maintenance (T+M) Periods (Day 99)

  19. Change from Baseline in Laboratory parameters (Chemistry) (Part 1)

    Time frame: Baseline (28 days), end of the combined Titration and Maintenance (T+M) Periods (Day 99)

  20. Change from Baseline in Laboratory Parameters (Urinalysis) (Part 1)

    Time frame: Baseline (28 days), end of the combined Titration and Maintenance (T+M) Periods (Day 99)

  21. Change from Baseline in Vital signs (Blood pressure) (Part 1)

    Time frame: Baseline (28 days), end of the combined Titration and Maintenance (T+M) Periods (Day 99)

  22. Change from Baseline in Vital signs (Heart rate) (Part 1)

    Time frame: Baseline (28 days), end of the combined Titration and Maintenance (T+M) Periods (Day 99)

  23. Change from Baseline in Vital signs (Temperature) (Part 1)

    Time frame: Baseline (28 days), end of the combined Titration and Maintenance (T+M) Periods (Day 99)

  24. Change from Baseline in Vital signs (Respiratory rate) (Part 1)

    Time frame: Baseline (28 days), end of the combined Titration and Maintenance (T+M) Periods (Day 99)

  25. Change from Baseline in Body Weight (Part 1)

    Time frame: Baseline (28 days), end of the combined Titration and Maintenance (T+M) Periods (Day 99)

  26. Change from Baseline in Tanner Staging (Part 1)

    Time frame: Baseline (28 days), end of the combined Titration and Maintenance (T+M) Periods (Day 99)

  27. Percentage Change from Baseline in CMSF (Part 2)

    The median percentage change from the Baseline in monthly (per 28 days) CMSF during the OLE Treatment Period.

    Time frame: Baseline (28 days), OLE1 Treatment Period (up to 52 weeks)

  28. Categorized Percentage Change in Seizures from Baseline in CMSF (Part 2)

    The categorized percentage change in seizures from the Baseline in monthly (per 28 days) CMSF during OLE Treatment Period will be presented in the following categories: no reduction or worsening, ≥25%, ≥50%, ≥75%, or 100% reduction.

    Time frame: Baseline (28 days), OLE1 Treatment Period (up to 52 weeks)

  29. Percentage of Participants who Achieve "Near Seizure Freedom" (Part 2)

    The percentage of participants who achieve near seizure freedom, defined as 0 or 1 seizures, during the OLE Treatment Period.

    Time frame: OLE1 Treatment Period (up to 52 weeks)

  30. Percentage of Participants with a CGI-I Rating of 'Much or Very Much Improved' as Assessed by the Investigator (Part 2)

    The percentage of participants who achieve a CGI-I rating of much or very much improved as assessed by the Investigator at the OLE Treatment Period.

    Time frame: At the End of the OLE1 Treatment Period (up to 52 weeks)

  31. Percentage of Participants with a CGI-I Rating of 'Much or Very Much Improved' as Assessed by the Parent/Caregiver (Part 2)

    The percentage of participants who achieve a CGI-I rating of much or very much improved as assessed by the parent/caregiver at the OLE Treatment Period.

    Time frame: At the End of the OLE1 Treatment Period (up to 52 weeks)

  32. Percentage of Participants with Improvement (Minimal, Much or Very Much Improved) on the CGI-I Rating as Assessed, Independently, by the Investigator (Part 2)

    The percentage of participants who achieve a CGI-I rating of minimal, much or very much improved as assessed by the Investigator at the OLE Treatment Period.

    Time frame: At the End of the OLE1 Treatment Period (up to 52 weeks)

  33. Percentage of Participants with Improvement (Minimal, Much or Very Much Improved) on the CGI-I Rating as Assessed by the Parent/Caregiver (Part 2)

    The percentage of participants who achieve a CGI-I rating of minimal, much or very much improved as assessed by the parent/caregiver at the OLE Treatment Period.

    Time frame: At the End of the OLE1 Treatment Period (up to 52 weeks)

  34. Percentage Change from Baseline in Monthly GTC Seizure Frequency (Part 2)

    The median percentage change from baseline in monthly GTC seizure frequency during OLE Treatment Period.

    Time frame: Baseline (28 days), OLE1 Treatment Period (up to 52 weeks)

  35. Change from Baseline in the Monthly Frequency of CMS-free Days (Part 2)

    The change from the Baseline in the monthly (per 28 days) frequency of CMS-free days during the OLE Treatment Period.

    Time frame: Baseline (28 days), OLE1 Treatment Period (up to 52 weeks)

07

Study locations

46 sites
  • Ep0216 154
    Birmingham, Alabama 35233, United States
  • Ep0216 144
    Los Angeles, California 90095, United States
  • Ep0216 101
    San Francisco, California 94158, United States
  • Ep0216 173
    Aurora, Colorado 80045, United States
  • Ep0216 149
    Washington D.C., District of Columbia 20010, United States
  • Ep0216 157
    Atlanta, Georgia 30329, United States
  • Ep0216 113
    Brookline, Massachusetts 02115, United States
  • Ep0216 134
    Detroit, Michigan 48201, United States
  • Ep0216 166
    Chapel Hill, North Carolina 27514, United States
  • Ep0216 164
    Cleveland, Ohio 44195, United States
  • Ep0216 120
    Philadelphia, Pennsylvania 19104-4318, United States
  • Ep0216 124
    Memphis, Tennessee 38105, United States
  • Ep0216 171
    Austin, Texas 78731, United States
  • Ep0216 2505
    Linz, Austria
  • Ep0216 804
    Brussels, Belgium
  • Ep0216 801
    Edegem, Belgium
  • Ep0216 2802
    Tbilisi, Georgia
  • Ep0216 902
    Bielefeld, Germany
  • Ep0216 909
    Kehl-kork, Germany
  • Ep0216 908
    Kiel, Germany
  • Ep0216 901
    Vogtareuth, Germany
  • Ep0216 1803
    Dublin, Ireland
  • Ep0216 1909
    Petah Tikva, Israel
  • Ep0216 1906
    Ramat Gan, Israel
  • Ep0216 1904
    Tel Aviv, Israel
  • Ep0216 1201
    Florence, Italy
  • Ep0216 1204
    Genova, Italy
  • Ep0216 1212
    Modena, Italy
  • Ep0216 1206
    Roma, Italy
  • Ep0216 1208
    Roma, Italy
  • Ep0216 1202
    Verona, Italy
  • Ep0216 1512
    Hiroshima, Japan
  • Ep0216 1505
    Niigata, Japan
  • Ep0216 1518
    Omura-shi, Japan
  • Ep0216 1502
    Shizuoka, Japan
  • Ep0216 1401
    Zwolle, Netherlands
  • Ep0216 2104
    Lisbon, Portugal
  • Ep0216 2105
    Porto, Portugal
  • Ep0216 1103
    Barcelona, Spain
  • Ep0216 1117
    Madrid, Spain
  • Ep0216 1118
    Santiago de Compostela, Spain
  • Ep0216 3101
    Dubai, United Arab Emirates
  • Ep0216 607
    Bristol, United Kingdom
  • Ep0216 602
    London, United Kingdom
  • Ep0216 611
    Manchester, United Kingdom
  • Ep0216 604
    Sheffield, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2022 (actual). Primary completion is estimated for Nov 2027, 68 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2021
First posted
Oct 1, 2021
StartActual
Mar 8, 2022
Primary completionEst.
Nov 8, 2027
CompletionEst.
Nov 8, 2027
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05064878
Lead sponsor
Zogenix, Inc.
Responsible party
Sponsor
First posted
Oct 1, 2021
Start date
Mar 8, 2022
Primary completion
Nov 8, 2027 (estimated)
Completion
Nov 8, 2027 (estimated)
Last update
Apr 29, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenfluramine

Start the discussion